NasdaqGS - Delayed Quote • USD
Geron Corporation (GERN)
At close: April 24 at 4:00 PM EDT
After hours: April 24 at 7:43 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | -0.1 | -0.1 | -0.34 | -0.15 |
| Low Estimate | -0.1 | -0.12 | -0.39 | -0.37 |
| High Estimate | -0.09 | -0.1 | -0.31 | -0.01 |
| Year Ago EPS | -0.07 | -0.09 | -0.32 | -0.34 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | 30k | 30k | 54.24M | 230.39M |
| Low Estimate | -- | -- | 8.99M | 39.91M |
| High Estimate | 150k | 150k | 99.35M | 378.55M |
| Year Ago Sales | 21k | 29k | 237k | 54.24M |
| Sales Growth (year/est) | 42.90% | 3.40% | 22,786.10% | 324.80% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.1 | -0.08 | -0.1 | -0.1 |
| EPS Actual | -0.07 | -0.09 | -0.08 | -0.09 |
| Difference | 0.03 | -0.01 | 0.02 | 0.01 |
| Surprise % | 30.00% | -12.50% | 20.00% | 10.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.1 | -0.1 | -0.34 | -0.15 |
| 7 Days Ago | -0.1 | -0.11 | -0.33 | -0.17 |
| 30 Days Ago | -0.1 | -0.11 | -0.33 | -0.17 |
| 60 Days Ago | -0.12 | -0.12 | -0.36 | -0.14 |
| 90 Days Ago | -0.12 | -0.12 | -0.36 | -0.11 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | -- | -- |
| Up Last 30 Days | -- | 1 | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | GERN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -42.90% | -- | -- | 1.50% |
| Next Qtr. | -11.10% | -- | -- | 11.40% |
| Current Year | -6.30% | -- | -- | 5.20% |
| Next Year | 55.90% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 5.00% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Needham: Buy to Buy | 4/11/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 4/10/2024 |
| Maintains | Needham: Buy to Buy | 3/15/2024 |
| Maintains | Goldman Sachs: Buy to Buy | 3/15/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 3/15/2024 |
| Reiterates | Needham: Buy to Buy | 3/13/2024 |
Related Tickers
MAIA MAIA Biotechnology, Inc.
2.6900
+9.35%
IBRX ImmunityBio, Inc.
4.8200
-12.20%
AGEN Agenus Inc.
7.42
+14.86%
VNDA Vanda Pharmaceuticals Inc.
4.5600
-1.51%
LCTX Lineage Cell Therapeutics, Inc.
1.1000
-3.51%
INCY Incyte Corporation
51.74
+0.17%
IOVA Iovance Biotherapeutics, Inc.
11.71
-1.26%
ALT Altimmune, Inc.
7.08
-6.47%
CDTX Cidara Therapeutics, Inc.
12.29
+19.90%
MDGL Madrigal Pharmaceuticals, Inc.
204.65
-6.29%